FURUKAWA Yusuke

FacultyDivisionofStemCellRegulation,CenterforMolecularMedicine
Job titleProfessorWeb site

Profile

Research Keywords

    Hematology, Molecular Biology, Molecular Oncology

Research Areas

  • Biological science / Molecular biology
  • Biological science / Cell biology
  • Clinical internal medicine / Hematology

Career

  •       Jichi Medical School
  •       Institute, Harvard Medical School
  •       Jichi Medical School
  •     Regulation, Jichi Medical School
  • Jichi Medical School
  • 1987
    -
    1988
    Research Associate, Division of Hemopoiesis,
  • 1988
    -
    1990
    Research Fellow, Dana-Farber Cancer
  • 1992
    -
    1999
    Assistant Professor, Division of Hemopoiesis,
  • 1999
    - Associate Professor, Division of Stem Cell
  • 2003
    - Professor, Division of Stem Cell Regulation,

Academic Background

  • -
    1982
    School of Medicine, University of Tsukuba (japan)

Academic Societies

  • American Society of Hematology
  • International Society for Experimental Hematology
  • American Association for the Advancement of Science
  • International Society of Hematology
  • ASBMB
Display all
Academic Societiesclose
  • American Society of Hematology
  • International Society for Experimental Hematology
  • American Association for the Advancement of Science
  • International Society of Hematology
  • ASBMB

Committee Career

  • 2000
    -
    2003
    International Society for Experimental Hematology Editorial Board
Display all
Committeeclose
  • 2000
    -
    2003
    International Society for Experimental Hematology Editorial Board

Research Activities

Papers(paper)

  • Phosphorylation-mediated EZH2 Inactivation Promotes Drug Resistance in Multiple Myeloma.
    Kikuchi K, Koyama D, Wada T, Izumi T, Hofgaard PO, Bogen B, Furukawa Y
    J. Clin. Invest. Oct. 2015
  • Overexpression of the Shortest Isoform of Histone Demethylase LSD1 Primes Hematopoietic Stem Cells for Malignant Transformation.
    Wada, T., Koyama, D., Kikuchi, J., Honda, H. and Furukawa, Y.
    Blood 125 3731-3746 Jun. 2015
  • Arf Tumor Suppressor Disrupts the Oncogenic Positive Feedback Loop Including c-Myc and DDX5.
    Tago, K., Funakoshi-Tago, M., Itoh, H., Furukawa, Y., Kikuchi, J., Kato, T., Suzuki, K. and Yanagisawa, K.
    Oncogene 34 310-318 Feb. 2015
  • [The mechanisms of drug resistance via the interaction of myeloma cells with stromal cells].
    Kikuchi J, Furukawa Y
    Nihon rinsho. Japanese journal of clinical medicine 73 57-61 Jan. 2015
  • Molecular Pathogenesis of Multiple Myeloma
    Furukawa Y and Kikuchi J
    Int. J. Clin. Oncol.(20) 413-422 2015
  • [DNA methyltransferase inhibitors * histone deacetylase inhibitors].
    Kikuchi J, Furukawa Y
    Nihon rinsho. Japanese journal of clinical medicine 72 1136-1142 Jun. 2014
  • Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
    Kikuchi J, Koyama D, Mukai HY, Furukawa Y
    International journal of hematology 99 726-736 Jun. 2014
  • Proteasome Inhibitors Exert Cytotoxicity and Increase Chemosensitivity via Transcriptional Repression of Notch1 in T-cell Acute Lymphoblastic Leukemia.
    Koyama, D., Kikuchi, J., Hiraoka, N., Wada, T., Kurosawa, H., Chiba, S. and Furukawa, Y.
    Leukemia 28 1216-1226 Jan. 2014
  • Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
    Hiraoka N, Kikuchi J, Yamauchi T, Koyama D, Wada T, Uesawa M, Akutsu M, Mori S, Nakamura Y, Ueda T, Kano Y, Furukawa Y
    PLoS One 9 e90675 2014
  • Romidepsin overcomes cell adhesion-mediated drug resistance in multiple myeloma cells.
    Sripayap P, Nagai T, Hatano K, Kikuchi J, Furukawa Y, Ozawa K
    Acta haematologica 132 1-4 2014
Display all
Papers(paper)close
  • Phosphorylation-mediated EZH2 Inactivation Promotes Drug Resistance in Multiple Myeloma.
    Kikuchi K, Koyama D, Wada T, Izumi T, Hofgaard PO, Bogen B, Furukawa Y
    J. Clin. Invest. Oct. 2015
  • Overexpression of the Shortest Isoform of Histone Demethylase LSD1 Primes Hematopoietic Stem Cells for Malignant Transformation.
    Wada, T., Koyama, D., Kikuchi, J., Honda, H. and Furukawa, Y.
    Blood 125 3731-3746 Jun. 2015
  • Arf Tumor Suppressor Disrupts the Oncogenic Positive Feedback Loop Including c-Myc and DDX5.
    Tago, K., Funakoshi-Tago, M., Itoh, H., Furukawa, Y., Kikuchi, J., Kato, T., Suzuki, K. and Yanagisawa, K.
    Oncogene 34 310-318 Feb. 2015
  • [The mechanisms of drug resistance via the interaction of myeloma cells with stromal cells].
    Kikuchi J, Furukawa Y
    Nihon rinsho. Japanese journal of clinical medicine 73 57-61 Jan. 2015
  • Molecular Pathogenesis of Multiple Myeloma
    Furukawa Y and Kikuchi J
    Int. J. Clin. Oncol.(20) 413-422 2015
  • [DNA methyltransferase inhibitors * histone deacetylase inhibitors].
    Kikuchi J, Furukawa Y
    Nihon rinsho. Japanese journal of clinical medicine 72 1136-1142 Jun. 2014
  • Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
    Kikuchi J, Koyama D, Mukai HY, Furukawa Y
    International journal of hematology 99 726-736 Jun. 2014
  • Proteasome Inhibitors Exert Cytotoxicity and Increase Chemosensitivity via Transcriptional Repression of Notch1 in T-cell Acute Lymphoblastic Leukemia.
    Koyama, D., Kikuchi, J., Hiraoka, N., Wada, T., Kurosawa, H., Chiba, S. and Furukawa, Y.
    Leukemia 28 1216-1226 Jan. 2014
  • Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
    Hiraoka N, Kikuchi J, Yamauchi T, Koyama D, Wada T, Uesawa M, Akutsu M, Mori S, Nakamura Y, Ueda T, Kano Y, Furukawa Y
    PLoS One 9 e90675 2014
  • Romidepsin overcomes cell adhesion-mediated drug resistance in multiple myeloma cells.
    Sripayap P, Nagai T, Hatano K, Kikuchi J, Furukawa Y, Ozawa K
    Acta haematologica 132 1-4 2014
  • [Molecular oncogenesis of multiple myeloma].
    Furukawa Y
    [Rinsho ketsueki] The Japanese journal of clinical hematology 54 1867-1875 Oct. 2013
  • The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
    Kikuchi J, Yamada S, Koyama D, Wada T, Nobuyoshi M, Izumi T, Akutsu M, Kano Y, Furukawa Y
    The Journal of biological chemistry 288 25593-25602 Aug. 2013
  • [How to overcome the cell adhesion-mediated drug resistance in multiple myeloma].
    Furukawa Y, Kikuchi J
    [Rinsho ketsueki] The Japanese journal of clinical hematology 54 513-521 Jun. 2013
  • Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding.
    Kikuchi J, Shibayama N, Yamada S, Wada T, Nobuyoshi M, Izumi T, Akutsu M, Kano Y, Sugiyama K, Ohki M, Park SY, Furukawa Y
    PloS one 8 e60649 2013
  • Reduced histone H3K9 acetylation of clock genes and abnormal glucose metabolism in ob/ob mice.
    Ishikawa-Kobayashi E, Ushijima K, Ando H, Maekawa T, Takuma M, Furukawa Y, Fujimura A
    Chronobiology international 29 982-993 Oct. 2012
  • Promoter methylation confers kidney-specific expression of the Klotho gene.
    Azuma M, Koyama D, Kikuchi J, Yoshizawa H, Thasinas D, Shiizaki K, Kuro-o M, Furukawa Y, Kusano E
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology 26 4264-4274 Oct. 2012
  • Latexin regulates the abundance of multiple cellular proteins in hematopoietic stem cells.
    Mitsunaga K, Kikuchi J, Wada T, Furukawa Y
    Journal of cellular physiology 227 1138-1147 Mar. 2012
  • Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8.
    Wada T, Kikuchi J, Furukawa Y
    EMBO reports 13 142-149 Feb. 2012
  • [Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
    Furukawa Y, Hiraoka N, Wada T, Kikuchi J, Kano Y
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica 138 26-32 Jul. 2011
  • Vinculin is indispensable for repopulation by hematopoietic stem cells, independent of integrin function.
    Ohmori T, Kashiwakura Y, Ishiwata A, Madoiwa S, Mimuro J, Furukawa Y, Sakata Y
    The Journal of biological chemistry 285 31763-31773 Oct. 2010
  • Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).
    Hirose K, Inukai T, Kikuchi J, Furukawa Y, Ikawa T, Kawamoto H, Oram SH, G?ttgens B, Kiyokawa N, Miyagawa Y, Okita H, Akahane K, Zhang X, Kuroda I, Honna H, Kagami K, Goi K, Kurosawa H, Look AT, Matsui H, Inaba T, Sugita K
    Blood 116 962-970 Aug. 2010
  • Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.
    Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K, Noborio-Hatano K, Nobuyoshi M, Ozawa K, Kano Y, Furukawa Y
    Blood 116 406-417 Jul. 2010
  • Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells.
    Okuya M, Kurosawa H, Kikuchi J, Furukawa Y, Matsui H, Aki D, Matsunaga T, Inukai T, Goto H, Altura RA, Sugita K, Arisaka O, Look AT, Inaba T
    The Journal of biological chemistry 285 1850-1860 Jan. 2010
  • The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
    Tanaka M, Kano Y, Akutsu M, Tsunoda S, Izumi T, Yazawa Y, Miyawaki S, Mano H, Furukawa Y
    Anticancer research 29 4589-4596 Nov. 2009
  • Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro.
    Kano Y, Tanaka M, Akutsu M, Mori K, Yazawa Y, Mano H, Furukawa Y
    Cancer chemotherapy and pharmacology 64 1129-1137 Nov. 2009
  • Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors.
    Wada T, Kikuchi J, Nishimura N, Shimizu R, Kitamura T, Furukawa Y
    The Journal of biological chemistry 284 30673-30683 Oct. 2009
  • Ablation of neutral cholesterol ester hydrolase 1 accelerates atherosclerosis.
    Sekiya M, Osuga J, Nagashima S, Ohshiro T, Igarashi M, Okazaki H, Takahashi M, Tazoe F, Wada T, Ohta K, Takanashi M, Kumagai M, Nishi M, Takase S, Yahagi N, Yagyu H, Ohashi K, Nagai R, Kadowaki T, Furukawa Y, Ishibashi S
    Cell metabolism 10 219-228 Sep. 2009
  • A novel missense mutation of ABCA1 in transmembrane alpha-helix in a Japanese patient with Tangier disease.
    Maekawa M, Kikuchi J, Kotani K, Nagao K, Odgerel T, Ueda K, Kawano M, Furukawa Y, Sakurabayashi I
    Atherosclerosis 206 216-222 Sep. 2009
  • Transactivation of RON receptor tyrosine kinase by interaction with PDGF receptor beta during steady-state growth of human mesangial cells.
    Kobayashi T, Furukawa Y, Kikuchi J, Ito C, Miyata Y, Muto S, Tanaka A, Kusano E
    Kidney international 75 1173-1183 Jun. 2009
  • [Epigenetics in hematological disorders].
    Furukawa Y
    [Rinsho ketsueki] The Japanese journal of clinical hematology 49 1472-1482 Oct. 2008
  • Ras-mediated up-regulation of survivin expression in cytokine-dependent murine pro-B lymphocytic cells.
    Shinjyo T, Kurosawa H, Miyagi J, Ohama K, Masuda M, Nagasaki A, Matsui H, Inaba T, Furukawa Y, Takasu N
    The Tohoku journal of experimental medicine 216 25-34 Sep. 2008
  • Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma.
    Murakami T, Sato A, Chun NA, Hara M, Naito Y, Kobayashi Y, Kano Y, Ohtsuki M, Furukawa Y, Kobayashi E
    The Journal of investigative dermatology 128 1506-1516 Jun. 2008
  • Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice.
    Inaba T, Yagyu H, Itabashi N, Tazoe F, Fujita N, Nagashima S, Okada K, Okazaki M, Furukawa Y, Ishibashi S
    Hypertension research : official journal of the Japanese Society of Hypertension 31 999-1005 May 2008
  • CD43, but not P-selectin glycoprotein ligand-1, functions as an E-selectin counter-receptor in human pre-B-cell leukemia NALL-1.
    Nonomura C, Kikuchi J, Kiyokawa N, Ozaki H, Mitsunaga K, Ando H, Kanamori A, Kannagi R, Fujimoto J, Muroi K, Furukawa Y, Nakamura M
    Cancer research 68 790-799 Feb. 2008
  • Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin's lymphoma: a review of 59 consecutive cases treated at a single institute.
    Akutsu M, Tsunoda S, Izumi T, Tanaka M, Katano S, Inoue K, Igarashi S, Hirabayashi K, Furukawa Y, Ohmine K, Sato K, Kobayashi H, Ozawa K, Kirito K, Nagashima T, Teramukai S, Fukushima M, Kano Y
    Oncology research 17 137-149 2008
  • Activation of focal adhesion kinase in detached human epidermal cancer cells and their long-term survival might be associated with cell surface expression of laminin-5.
    Katayama H, Yamane Y, Furukawa Y, Kitagawa S, Nakamura Y, Yoshino K
    Acta dermato-venereologica 88 100-107 2008
  • E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1.
    Kikuchi J, Shimizu R, Wada T, Ando H, Nakamura M, Ozawa K, Furukawa Y
    Stem cells (Dayton, Ohio) 25 2439-2447 Oct. 2007
  • Rad9 modulates the P21WAF1 pathway by direct association with p53.
    Ishikawa K, Ishii H, Murakumo Y, Mimori K, Kobayashi M, Yamamoto K, Mori M, Nishino H, Furukawa Y, Ichimura K
    BMC molecular biology 8 37 May 2007
  • Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
    Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Mano H, Furukawa Y
    Investigational new drugs 25 31-40 Feb. 2007
  • Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro.
    Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Inoue K, Mori K, Fujii H, Mano H, Odgerel T, Furukawa Y
    Oncology research 16 85-95 2006
  • Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K, Kobayashi Y, Takatoku MA, Ozawa K, Kano Y, Ishii H, Furukawa Y
    Acta haematologica 115 78-90 2006
  • Frag1, a homolog of alternative replication factor C subunits, links replication stress surveillance with apoptosis.
    Ishii H, Inageta T, Mimori K, Saito T, Sasaki H, Isobe M, Mori M, Croce CM, Huebner K, Ozawa K, Furukawa Y
    Proceedings of the National Academy of Sciences of the United States of America 102 9655-9660 Jul. 2005
  • Methylation silencing of the Apaf-1 gene in acute leukemia.
    Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, Ishii H, Furukawa Y
    Molecular cancer research : MCR 3 325-334 Jun. 2005
  • Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
    Sutheesophon K, Nishimura N, Kobayashi Y, Furukawa Y, Kawano M, Itoh K, Kano Y, Ishii H, Furukawa Y
    Journal of cellular physiology 203 387-397 May 2005
  • Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites.
    Ishii H, Mimori K, Inageta T, Murakumo Y, Vecchione A, Mori M, Furukawa Y
    Molecular cancer research : MCR 3 130-138 Mar. 2005
  • Differential roles of E-type cyclins during transformation of murine E2F-1-deficient cells.
    Ishii H, Mimori K, Yoshikawa Y, Mori M, Furukawa Y, Vecchione A
    DNA and cell biology 24 173-179 Mar. 2005
  • Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y, Akutsu M, Tsunoda S, Izumi T, Mori K, Fujii H, Yazawa Y, Mano H, Furukawa Y
    Cancer chemotherapy and pharmacology 54 505-513 Dec. 2004
  • Differentially expressed genes execute zinc-induced apoptosis in precancerous esophageal epithelium of zinc-deficient rats.
    Ishii H, Vecchione A, Furukawa Y, Croce CM, Huebner K, Fong LY
    Oncogene 23 8040-8048 Oct. 2004
  • Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect.
    Kawano T, Horiguchi-Yamada J, Iwase S, Akiyama M, Furukawa Y, Kan Y, Yamada H
    Anticancer research 24 2705-2712 Sep. 2004
  • Role of cyclins in cAMP inhibition of glomerular mesangial cell proliferation.
    Ito C, Yamamoto H, Furukawa Y, Takeda S, Akimoto T, Iimura O, Ando Y, Asano Y, Kusano E
    Clinical science (London, England : 1979) 107 81-87 Jul. 2004
  • Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells.
    Kawano T, Horiguchi-Yamada J, Saito S, Iwase S, Furukawa Y, Kano Y, Yamada H
    Leukemia research 28 623-629 Jun. 2004
  • Alterations of common chromosome fragile sites in hematopoietic malignancies.
    Ishii H, Furukawa Y
    International journal of hematology 79 238-242 Apr. 2004
  • Effect of exogenous E2F-1 on the expression of common chromosome fragile site genes, FHIT and WWOX.
    Ishii H, Mimori K, Vecchione A, Sutheesophon K, Fujiwara T, Mori M, Furukawa Y
    Biochemical and biophysical research communications 316 1088-1093 Apr. 2004
  • Cancer prevention and therapy in a preclinical mouse model: impact of FHIT viruses.
    Ishii H, Vecchione A, Fong LY, Zanesi N, Trapasso F, Furukawa Y, Baffa R, Huebner K, Croce CM
    Current gene therapy 4 53-63 Mar. 2004
  • Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it.
    Kawano T, Horiguchi-Yamada J, Iwase S, Furukawa Y, Kano Y, Yamada H
    Molecular and cellular biochemistry 258 25-33 Mar. 2004
  • Alteration of the fragile histidine triad gene early in carcinogenesis: an update.
    Ishii H, Ozawa K, Furukawa Y
    Journal of experimental therapeutics & oncology 3 291-296 Nov. 2003
  • Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
    Ishii H, Vecchione A, Furukawa Y, Sutheesophon K, Han SY, Druck T, Kuroki T, Trapasso F, Nishimura M, Saito Y, Ozawa K, Croce CM, Huebner K, Furukawa Y
    Molecular cancer research : MCR 1 940-947 Nov. 2003
  • Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c.
    Nishimura N, Furukawa Y, Sutheesophon K, Nakamura M, Kishi K, Okuda K, Sato Y, Kano Y
    Oncogene 22 4074-4082 Jun. 2003
  • A novel I-branching beta-1,6-N-acetylglucosaminyltransferase involved in human blood group I antigen expression.
    Inaba N, Hiruma T, Togayachi A, Iwasaki H, Wang XH, Furukawa Y, Sumi R, Kudo T, Fujimura K, Iwai T, Gotoh M, Nakamura M, Narimatsu H
    Blood 101 2870-2876 Apr. 2003
  • Identification of novel p53-binding proteins by biomolecular interaction analysis combined with tandem mass spectrometry.
    Kikuchi J, Furukawa Y, Hayashi N
    Molecular biotechnology 23 203-212 Mar. 2003
  • Modulation of the erythropoietin-induced proliferative pathway by cAMP in vascular smooth muscle cells.
    Ito C, Kusano E, Furukawa Y, Yamamoto H, Takeda S, Akimoto T, Iimura O, Ando Y, Asano Y
    American journal of physiology. Cell physiology 283 C1715-21 Dec. 2002
  • Vasoactive intestinal peptide and cytokines enhance stem cell factor production from epidermal keratinocytes DJM-1.
    Kakurai M, Fujita N, Kiyosawa T, Inoue T, Ishibashi S, Furukawa Y, Demitsu T, Nakagawa H
    The Journal of investigative dermatology 119 1183-1188 Nov. 2002
  • Apaf-1 is a mediator of E2F-1-induced apoptosis.
    Furukawa Y, Nishimura N, Furukawa Y, Satoh M, Endo H, Iwase S, Yamada H, Matsuda M, Kano Y, Nakamura M
    The Journal of biological chemistry 277 39760-39768 Oct. 2002
  • Differences in E2F subunit expression in quiescent and proliferating vascular smooth muscle cells.
    Fujita N, Furukawa Y, Itabashi N, Okada K, Saito T, Ishibashi S
    American journal of physiology. Heart and circulatory physiology 283 H204-12 Jul. 2002
  • [Effectiveness of prolonged oral administration of low-dose etoposide in a case of malignant lymphoma in the mesenterium].
    Sato T, Yanagihara M, Sato K, Nozawa T, Furukawa Y, Imanishi H, Kouzuma T
    Gan to kagaku ryoho. Cancer & chemotherapy 29 959-962 Jun. 2002
  • Hyperglycemia enhances VSMC proliferation with NF-kappaB activation by angiotensin II and E2F-1 augmentation by growth factors.
    Fujita N, Furukawa Y, Du J, Itabashi N, Fujisawa G, Okada K, Saito T, Ishibashi S
    Molecular and cellular endocrinology 192 75-84 Jun. 2002
  • Phosphorylation of Fanconi anemia protein, FANCA, is regulated by Akt kinase.
    Otsuki T, Nagashima T, Komatsu N, Kirito K, Furukawa Y, Kobayashi Si S, Liu JM, Ozawa K
    Biochemical and biophysical research communications 291 628-634 Mar. 2002
  • Cell cycle control genes and hematopoietic cell differentiation.
    Furukawa Y
    Leukemia & lymphoma 43 225-231 Feb. 2002
  • Cdc2 Gene Expression at the G1 to S Transition in Human T Lymphocytes.
    Furukawa, Y., Piwnica-Worms, H., Ernst, T.J., Kanakura, Y. and Griffin, J.D.
    Science 250 805-808 Dec. 1990
  • The Product of Retinoblastoma Susceptibility Gene Has Properties of a Cell Cycle Regulatory Element.
    DeCaprio, J.A., Ludlow, J.W., Lynch, D., Furukawa, Y., Griffin, J., Piwnica-Worms, H., Huang, C.-M. and Livingston, D.M.
    Cell 58 1085-1095 Sep. 1989

Outside Fund Adoption

  • The Role of Cell Cycle Control Genes in Hematopoietic Cell Differentiation
  • The Mechanisms of Cell Death in Hematopoietic Cells
  • Transcriptional Regulation of the Genes involved in hematopoietic differentiation
  • Development of novel cell cycle regulatory drugs
  • Biology of Hematopoietic Stem Cells
Display all
Outside Fund Adoptionclose
  • The Role of Cell Cycle Control Genes in Hematopoietic Cell Differentiation
  • The Mechanisms of Cell Death in Hematopoietic Cells
  • Transcriptional Regulation of the Genes involved in hematopoietic differentiation
  • Development of novel cell cycle regulatory drugs
  • Biology of Hematopoietic Stem Cells

Works

  • Development of a novel cDNA subtraction method
    1999
  • Application of centrifugal elutriator
    1996
  • Identification of novel p53- binding proteins by BIACORE-MASS
    2001
Display all
Worksclose
  • Development of a novel cDNA subtraction method
    1999
  • Application of centrifugal elutriator
    1996
  • Identification of novel p53- binding proteins by BIACORE-MASS
    2001


Copyright c MEDIA FUSION Co.,Ltd. All rights reserved.